Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744576 | 0.94 | ALDH1A1 (0.70) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL17297978 | 0.94 | ALDH1A1 (0.70) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL17297788 | 0.94 | ALDH1A1 (0.70) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL20749660 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL19194519 | 0.92 | KDM4E (0.68) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL3130725 | 0.92 | KDM4E (0.72) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL19194546 | 0.90 | KDM4E (0.65) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL19102404 | 0.90 | KDM4E (0.65) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL17481967 | 0.90 | ALDH1A1 (0.65) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL17297795 | 0.90 | ALDH1A1 (0.65) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-0871615-B1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6194581-B1 | FOR TREATMENT OF DYSFUNCTION OF THE CENTRAL OR AUTONOMIC NERVOUS SYSTEMS INCLUDING DEMENTIA, COGNITIVE DISORDERS, NEURODEGENERATIVE DISORDERS, EXTRAPYRAMIDAL DISORDERS, CONVULSIVE DISORDERS, CARDIOVASCULAR DISORDERS, PAIN | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| US-5852041-A | Substituted pyridines useful as modulators of acethylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0871615-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5736560-A | USEFUL IN THE TREATMENT OF ALZHEIMER'S AND PARKINSONS'S DISEASES | SIBIA NEUROSCIENCES, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5686473-A | TREATING PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, DEMENTIA AND PAIN | SIBIA NEUROSCIENCES, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5585388-A | Substituted pyridines useful as modulators of acetylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996031475-A2 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | KDM4E 1253/4885ALDH1A1 2070/4885CHRNB2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.